SCHEMBL7653357

SCHEMBL7653357

COc1nn(-c2ccc(N(C(C)=O)c3ccc(Cl)cc3)c(OCc3ccc(F)cc3)c2)c(=O)o1

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ABHD16A O95870 1/20 0.48
MGLL Q99685 4/20 0.41
FAAH O00519 3/20 0.41
KDM5A P29375 3/20 0.37
KDM5B Q9UGL1 3/20 0.37
KEAP1 Q14145 1/20 0.37
NFE2L2 Q16236 1/20 0.37
BCHE P06276 1/20 0.37
LIPC P11150 1/20 0.37
ACHE P22303 1/20 0.37
LIPE Q05469 1/20 0.37
KDM4A O75164 1/20 0.36
KDM2B Q8NHM5 1/20 0.36
KDM4C Q9H3R0 1/20 0.36
TBXA2R P21731 1/20 0.35
PTGER1 P34995 1/20 0.35
PTGER4 P35408 1/20 0.35
PTGER3 P43115 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7660520 0.81 MGLL (0.46) ABHD16AMGLLFAAHLIPCLIPE
SCHEMBL7047574 0.80 FAAH (0.49) ABHD16AMGLLFAAHKDM5AKDM5B
SCHEMBL7653362 0.80 FAAH (0.49) ABHD16AMGLLFAAHKDM5AKDM5B
SCHEMBL7046310 0.78 ABHD16A (0.61) ABHD16AMGLLFAAHKDM5AKDM5B
SCHEMBL7046290 0.76 ABHD16A (0.59) ABHD16AMGLLFAAHKDM5AKDM5B
SCHEMBL7043172 0.75 ABHD16A (0.57) ABHD16AMGLLFAAHBCHELIPC
SCHEMBL7045850 0.73 MGLL (0.72) ABHD16AMGLLFAAHBCHELIPC
SCHEMBL2233406 0.69 ABHD16A (0.72) ABHD16AMGLLFAAHLIPCLIPE
SCHEMBL7046273 0.68 FAAH (0.60) ABHD16AMGLLFAAHLIPCLIPE
SCHEMBL7044315 0.66 MGLL (0.62) ABHD16AMGLLFAAHLIPCLIPE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6369088-B2 ANTIDIABETIC AGENTS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2002-04-09 US disclosed
US-20010031772-A1 Substituted 3-phenyl-5-alkoxy-1,3,4-oxadiazol-2-ones, their preparation and their use as pharmaceuticals SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010031772-A1 Substituted 3-phenyl-5-alkoxy-1,3,4-oxadiazol-2-ones, their preparation and their use as pharmaceuticals CNR1, PTGER1, CNR2 ABHD16A 1922/4885MGLL 1542/4885FAAH 46/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.